Drug
Pelcitoclax
Pelcitoclax is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(2)
Detailed Status
Terminated1
Active, not recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
terminated133%
active_not_recruiting133%
withdrawn133%
Recent Activity
1 active trials
Showing 3 of 3
withdrawnphase_1
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
NCT07428486
active_not_recruitingphase_1
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504
terminatedphase_1
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
NCT04893759
Clinical Trials (3)
Showing 3 of 3 trials
NCT07428486Phase 1
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
NCT05691504Phase 1
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT04893759Phase 1
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3